Analysis of Candidate miRNAs' Expression in Pancreatic Cancer

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-11-08 DOI:10.1002/cam4.70400

Rabeah Al-Temaimi, Bicher Abdulkarim, Ali Al-Ali, Bency John, Mrinmay Kumar Mallik, Kusum Kapila

{"title":"Analysis of Candidate miRNAs' Expression in Pancreatic Cancer","authors":"Rabeah Al-Temaimi, Bicher Abdulkarim, Ali Al-Ali, Bency John, Mrinmay Kumar Mallik, Kusum Kapila","doi":"10.1002/cam4.70400","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Pancreatic cancer (PC) is one of the most aggressive types of cancer. Despite advances in molecular diagnostics, PC diagnosis relies on imaging technologies and morphological assessment of fine needle aspirates (FNAs). MicroRNA (miRNA) involvement in PC pathogenesis and potential diagnostics application have been suggested, albeit current supporting evidence is lacking. Here, we investigated the association of selected miRNAs with PC incidence and clinical characteristics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Fold expression of miR-216a-3p, -217-5p, -221-3p, -222-3p, and miR-196a-5p was assessed in 73 PC FNA cell-block sections and 6 healthy pancreas tissues using Taqman advanced miRNA assays. Potential miRNA targets were ascertained using immunocytochemistry.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>miR-196a-5p was upregulated in PC compared to healthy pancreatic tissue (<i>β</i> = −0.05, 95% CI: −0.065 – (−0.035); <i>p</i> < 0.001). miR-221-3p and miR-222-3p fold expression were strongly correlated (<i>r</i> = 0.897, <i>p</i> < 0.001), whereas miR-196a-5p fold expression correlated with that of miR-221-3p (<i>r</i> = 0.688, <i>p</i> < 0.001) and miR-222-3p (<i>r</i> = 0.489, <i>p</i> < 0.001). Moreover, miR-196a-5p fold expression positively correlated with tumor stage (<i>r</i> = 0.32, <i>p</i> = 0.034). miR-217-5p fold expression inversely correlated with KRAS expression (<i>r</i> = -0.69, <i>p</i> = 0.0027).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study shows miR-196a-5p has reasonable specificity to PC and thus may have diagnostic and prognostic potential in PC as proposed in the literature. Moreover, KRAS and NFKBIA may be potential targets for miR-217-5p and miR-196a-5p, respectively. Thus, these miRNAs may be involved in tumor progression and may have valuable applications in novel therapeutics or treatment monitoring.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 21","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544394/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70400","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Pancreatic cancer (PC) is one of the most aggressive types of cancer. Despite advances in molecular diagnostics, PC diagnosis relies on imaging technologies and morphological assessment of fine needle aspirates (FNAs). MicroRNA (miRNA) involvement in PC pathogenesis and potential diagnostics application have been suggested, albeit current supporting evidence is lacking. Here, we investigated the association of selected miRNAs with PC incidence and clinical characteristics.

Methods

Fold expression of miR-216a-3p, -217-5p, -221-3p, -222-3p, and miR-196a-5p was assessed in 73 PC FNA cell-block sections and 6 healthy pancreas tissues using Taqman advanced miRNA assays. Potential miRNA targets were ascertained using immunocytochemistry.

Results

miR-196a-5p was upregulated in PC compared to healthy pancreatic tissue (β = −0.05, 95% CI: −0.065 – (−0.035); p < 0.001). miR-221-3p and miR-222-3p fold expression were strongly correlated (r = 0.897, p < 0.001), whereas miR-196a-5p fold expression correlated with that of miR-221-3p (r = 0.688, p < 0.001) and miR-222-3p (r = 0.489, p < 0.001). Moreover, miR-196a-5p fold expression positively correlated with tumor stage (r = 0.32, p = 0.034). miR-217-5p fold expression inversely correlated with KRAS expression (r = -0.69, p = 0.0027).

Conclusion

Our study shows miR-196a-5p has reasonable specificity to PC and thus may have diagnostic and prognostic potential in PC as proposed in the literature. Moreover, KRAS and NFKBIA may be potential targets for miR-217-5p and miR-196a-5p, respectively. Thus, these miRNAs may be involved in tumor progression and may have valuable applications in novel therapeutics or treatment monitoring.

Abstract Image

查看原文本刊更多论文

候选 miRNA 在胰腺癌中的表达分析

背景：胰腺癌（PC）是侵袭性最强的癌症类型之一。尽管分子诊断技术不断进步，但 PC 的诊断仍依赖于成像技术和细针穿刺（FNA）的形态学评估。有人认为，微 RNA（miRNA）参与了 PC 的发病机制和潜在的诊断应用，但目前还缺乏支持性证据。在此，我们研究了部分miRNA与PC发病率和临床特征的关系：方法：使用 Taqman 高级 miRNA 检测法评估了 73 个 PC FNA 细胞块切片和 6 个健康胰腺组织中 miR-216a-3p、-217-5p、-221-3p、-222-3p 和 miR-196a-5p 的折叠表达。结果：与健康胰腺组织相比，miR-196a-5p 在 PC 中上调（β = -0.05，95% CI：-0.065 - (-0.035)；p 结论：我们的研究表明，miR-196a-5p 在 PC 中上调：我们的研究表明，miR-196a-5p 对 PC 有合理的特异性，因此可能具有文献中提出的 PC 诊断和预后潜力。此外，KRAS 和 NFKBIA 可能分别是 miR-217-5p 和 miR-196a-5p 的潜在靶点。因此，这些 miRNA 可能参与了肿瘤的进展，并可能在新型疗法或治疗监测中具有重要应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.